Abstracts tagged "Scleroderma"

Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Voon H. Ong³ and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Daniel Ennis^1,2, Zareen Ahmad³, Keshini Devakandan¹, Melanie A Anderson⁴ and Sindhu Johnson¹, ¹Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network Library Services, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…
Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Rebecca B. Blank¹, Jessica K. Gordon², Jackie Szymonifka³, Shervin Assassi⁴, Elana J. Bernstein⁵, Flavia V. Castelino⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique Hinchcliff⁹, Kate Homer¹⁰, Ami A. Shah¹¹, Victoria Shanmugam¹², Virginia D. Steen¹³, Tracy M. Frech¹⁴ and Dinesh Khanna¹⁵, ¹Internal Medicine, New York Presbyterian-Weill Cornell Hospital, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Rheumatology, Columbia University, New York, NY, ⁶Rheumatology, Harvard Medical School, Boston, MA, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁰Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Rheumatology, The George Washington University, Washington, DC, ¹³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…
Abstract Number: 2711 • 2018 ACR/ARHP Annual Meeting
Comparison of Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis with That Associated with Other Diseases: Are There Differences?
Rabeea Mirza¹, Yuxuan Jin², Donald F. Kirby³ and Soumya Chatterjee^1,4, ¹Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Gastric antral vascular ectasia (GAVE) is a pathologic angioectasia with a characteristic endoscopic appearance. Rugal folds with dilated blood vessels radiate from the antrum…
Abstract Number: 2935 • 2018 ACR/ARHP Annual Meeting
A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification
Svetlana I. Nihtyanova¹, Emma C. Derrett-Smith², Carmen Maria Fonseca³, Voon H. Ong² and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Division of Medicine, University College London, London, United Kingdom, ³Department of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: The Le Roy et al. classification of SSc into limited and diffuse cutaneous subtype remains the most commonly used. Nevertheless, autoantibodies are much better…
Abstract Number: 2939 • 2018 ACR/ARHP Annual Meeting
Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis
Eric Dein¹, Laura K. Hummers², Christopher A. Mecoli^3,4 and Zsuzsanna McMahan⁵, ¹Department of Internal Medicine, Johns Hopkins Bayview, Baltimore, MD, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Although up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, clinical features of patients with severe lower gastrointestinal involvement are…
Abstract Number: 124 • 2018 ACR/ARHP Annual Meeting
M10, a Small Fragment of the Hepatocyte Growth Factor Receptor, Attenuates Fibrotic Changes in a Murine Model of Scleroderma Lung Disease and in Human Lung Fibroblasts
Tanjina Akter¹, Ilia Atanelishvili¹, Atsushi Noguchi², Galina S. Bogatkevich¹ and Rick Silver³, ¹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology, Endocrinology and Nephrology,, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Rheumatology, Medical University of SC, Charleston, SC
Background/Purpose: Interstitial lung disease (ILD) is the major cause of mortality among scleroderma (systemic sclerosis, SSc) patients. Extracellular matrix (ECM) deposition is a hallmark of…
Abstract Number: 750 • 2017 ACR/ARHP Annual Meeting
Diltiazem Gel As a New Local Treatment for Scleroderma Digital Ulcers
Mohammad Ali Nazarinia¹, Elmira Esmaeilzadeh² and Saeedeh Shenavandeh², ¹Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Shiraz, Iran (Islamic Republic of), ²Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran., Shiraz, Iran (Islamic Republic of)
Background/Purpose: Assessing the effect of Diltiazem gel on healing process of scleroderma digital ulcers and comparing its effect with Nitroglycerin ointment and placebo. Methods: Ninety…
Abstract Number: 1680 • 2017 ACR/ARHP Annual Meeting
Higher Baseline Monocyte Count Is Associated with More Extensive Skin Involvement and Higher Mortality in Systemic Sclerosis
Vishnu Mohan¹, Purvesh Khatri², Samuel Theodore¹, Julio Charles¹, Hau Pham¹, Deepthi Nair¹, Madeleine Scott², John D. Reveille¹, Maureen D. Mayes¹ and Shervin Assassi¹, ¹University of Texas McGovern Medical School, Houston, TX, ²Stanford University, Stanford, CA
Background/Purpose: Macrophages are the primary inflammatory cell type present in the systemic sclerosis (SSc) skin. Circulating monocytes can give rise to profibrotic inflammatory cells such…
Abstract Number: 2666 • 2017 ACR/ARHP Annual Meeting
The Clinical Utility of Flow-Mediated Dilation in Systemic Sclerosis Digital Ulcer Assessment
Tracy M. Frech¹, Daniel Machin², Maureen Murtaugh³ and Anthony Donato², ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ³University of Utah, Salt Lake, UT
Background/Purpose: Systemic sclerosis (SSc, scleroderma) patients can have the end-stage vasculopathy manifestation of a digital ulcer (DU). Brachial artery flow mediated dilation (FMD) is an…
Abstract Number: 2681 • 2017 ACR/ARHP Annual Meeting
Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome
Samar Alharbi¹, Zareen Ahmad², Zahi Touma³, Arthur Bookman⁴, Jorge Sánchez-Guerrero⁵ and Sindhu Johnson⁶, ¹Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health System, University Health Network,, Toronto, ON, Canada, ²Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁶Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health Systems and University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an immune disorder characterized by vasculopathy and fibrosis. SSc may overlap with another disease such as systemic lupus erythematosus (SLE).…
Abstract Number: 803 • 2016 ACR/ARHP Annual Meeting
Multi-Organ RNA-Sequencing of Systemic Sclerosis (SSc) Patients Shows Reproducible Gene Expression Profiles Across Organ Systems
Bhaven K. Mehta¹, Michael E. Johnson¹, Kimberly A. Archambault¹, Tammara A. Wood², Antonia Valenzuela³, Amanda Crawford⁴, David Fiorentino⁵, Nielsen Fernandez-Becker⁶, Laren Becker⁶, Linda Nguyen⁶, Francesco Boin⁷, Paul Wolters⁸, Lorinda Chung⁹ and Michael Whitfield², ¹Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Stanford University School of Medicine, Stanford, CA, ⁴Dermatology, Stanford University, Redwood City, CA, ⁵Dermatology, Stanford University, Stanford, CA, ⁶Gastroenterology & Hepatology, Stanford University School of Medicine, Palo Alto, CA, ⁷Rheumatology, University California San Francisco, San Francisco, CA, ⁸Pulmonary Division, Department of Medicine, University of California, San Francisco, San Francisco, CA, ⁹Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: While a hallmark of systemic sclerosis (SSc) is skin fibrosis, internal organ involvement is the primary cause of mortality. Pulmonary Arterial Hypertension (PAH), Interstitial…
Abstract Number: 1850 • 2016 ACR/ARHP Annual Meeting
Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Tomoya Watanabe¹, Tetsuya Nishimoto², Jonathan Heywood³, Stanley Hoffman⁴, Logan Mlakar⁴ and Carol A. Feghali-Bostwick⁵, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Rheumataology, Medical University of South Carolina, Chareston, SC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: The murine bleomycin (BLM)-induced fibrosis model is the most widely used in systemic sclerosis (SSc) studies. Traditionally, daily subcutaneous injections of BLM for 4-6…
Abstract Number: 2896 • 2016 ACR/ARHP Annual Meeting
Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers
Susan Armstrong¹, A. Wayne Evans², Zareen Ahmad³ and Sindhu R. Johnson⁴, ¹Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Hyperbaric Medicine Unit, Department of Anaesthesia, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Vascular complications of systemic sclerosis (SSc, scleroderma) can result in ulcers in the distal extremities, which limit function and are often refractory to conventional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].